Companies → Allurion Technologies, Inc.
Save to list
Remove

Allurion Technologies, Inc.

United States, Massachusetts, Natick
Description
by AI
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Recent news:

Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?

Here is how Allurion Technologies, Inc. (ALUR) and McKesson (MCK) have performed compared to their sector so far this year.

Source: Zacks Feb 27, 2026

Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion

Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.

Source: Zacks Nov 18, 2025

4 Medical Product Stocks to Watch From a Challenging Industry

The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.

Source: Zacks Nov 17, 2025

Allurion Technologies Inc (ALUR) Q3 2025 Earnings Call Highlights: Strategic Restructuring and ...

Allurion Technologies Inc (ALUR) reports significant operational improvements and FDA milestones, despite a decline in revenue and profit margins.

Source: GuruFocus.com Nov 12, 2025

Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates

Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of +12.31% and -43.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Zacks Aug 19, 2025

Allurion Technologies Inc (ALUR) Q2 2025 Earnings Call Highlights: Strategic Pivot and Cost ...

Allurion Technologies Inc (ALUR) reports significant revenue drop but highlights strategic advancements and cost-cutting measures in its Q2 2025 earnings call.

Source: GuruFocus.com Aug 14, 2025

NYSE - Delayed Quote - USD
ALUR
0.74 -0.06 (-7.63%)
At close March 20 20:00 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/21/2026
Market Cap: 11.04 M
Enterprise Value: 38.30 M
Trailing P/E: N/A
Forward P/E: 0.83
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 0.24
Price/Book (mrq): -0.07
Enterprise Value/Revenue: 2.23
Enterprise Value/EBITDA: -2.18
Financial Highlights
Profitability and Income Statement
Profit Margin: -187.87%
Return on Assets (ttm): -71.87%
Return on Equity (ttm): N/A%
Revenue (ttm): 17.21 M
Net Income Avi to Common (ttm): -32.33 M
Diluted EPS (ttm): -16.20
Balance Sheet and Cash Flow
Total Cash (mrq): 6.14 M
Total Debt/Equity (mrq): N/A%
Levered Free Cash Flow (ttm): -18.78 M
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.